BVT will have exclusive access to BIOGARD’s biological insecticide Beauveria bassiana ATCC 74040 for bee vectoring uses
Bee Vectoring Technologies International announced its first commercial agreement with BIOGARD, a division of CBC (Europe), one of the leading bio protectant companies in Europe. Through the agreement, BVT will have exclusive access to BIOGARD’s biological insecticide Beauveria bassiana ATCC 74040 for bee vectoring uses throughout the European Union and Switzerland.
“This first commercial agreement with a partner in the EU represents a major step in BVT’s growth,” said Michael Collinson, Chairman, BVT. “It is the most significant global milestone for BVT since acquiring EPA registration in the US in 2019. The agreement will enable BVT to operate in the EU through the development and registration of a bee-vectoring product extension of an already-accepted biological active substance, rather than awaiting approval of a new active substance submission – a process that can take up to 3 years. It is also a clear indication that the industry has begun to recognise the value of our bee vectoring system as an effective way to deliver crop protection.”
Through the agreement, BVT will develop a biological insecticide solution for delivery to crops through BVT’s proprietary bee vectoring platform using BIOGARD’s active substance registration. This could be either stacked alongside BVT’s biological fungicide, Clonostachys rosea strain CR-7 (CR-7), for a complete fungicidal plus insecticidal solution for certain crops, or used as a standalone when some diseases are not present. Bee vectoring uses up to 98 per cent less product per crop hectare compared to traditional application methods since the active ingredient is delivered directly to crop flowers with no waste. The agreement also includes a long-term arrangement for BIOGARD to supply the active substance to BVT.
